AI Article Synopsis

  • The study aimed to investigate the effects of the timing of P2Y inhibitor administration on myocardial necrosis during elective percutaneous coronary intervention (PCI), utilizing data from the ALPHEUS trial.
  • Results revealed that patients who received P2Y inhibitors closer to the PCI procedure had higher rates of myocardial necrosis compared to those who were given the medication earlier, with improved outcomes seen in groups that received longer loading times.
  • While the study found a correlation between timing and myocardial injury, it noted that bleeding complications were minimal and did not vary significantly among the different timing groups, leaving long-term clinical effects unclear.

Article Abstract

Background: There are dated and conflicting data about the optimal timing of initiation of P2Y inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI.

Methods: The ALPHEUS trial divided 1809 patients into quartiles of loading time. The ALPHEUS primary outcome was used (type 4 [a or b] myocardial infarction or major myocardial injury) as well as the main secondary outcome (type 4 [a or b] myocardial infarction or any type of myocardial injury).

Results: Patients in the first quartile group (Q1) presented higher rates of the primary outcome (P = 0.01). When compared with Q1, incidences of the primary outcome decreased in patients with longer loading times (adjusted odds ratio [adjOR], 0.70 [0.52.-0.95]; P = 0.02 for Q2; adjOR 0.65 [0.48-0.88]; P < 0.01 for Q3; adjOR 0.66 [0.49-0.89]; P < 0.01 for Q4). Concordant results were found for the main secondary outcome. There was no interaction with the study drug allocated by randomization (clopidogrel or ticagrelor). Bleeding complications (any bleeding ranging between 4.9% and 7.3% and only 1 major bleeding at 48 hours) and clinical ischemic events were rare and did not differ among groups.

Conclusions: In elective PCI, administration of the oral P2Y inhibitor at the time of PCI could be associated with more frequent periprocedural myocardial necrosis than an earlier administration. The long-term clinical consequences remain unknown.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cjca.2023.08.028DOI Listing

Publication Analysis

Top Keywords

p2y inhibitor
16
myocardial necrosis
16
loading time
12
primary outcome
12
type myocardial
12
inhibitor loading
8
elective pci
8
myocardial
8
periprocedural myocardial
8
ticagrelor clopidogrel
8

Similar Publications

As the aging population continues to grow, the incidence of osteoporotic fractures increases and is compounded by our lack of therapeutic strategies that increase bone formation. Although exercise and physical activity play a key role in maintaining bone mass throughout our lives, the loads and exertion required to elicit an anabolic response becomes exceedingly difficult to achieve with age. Based on previous work, the P2Y receptor offers a unique therapeutic target to increasing bone mass by modifying the mechanotransduction.

View Article and Find Full Text PDF

Use Of Cangrelor In Older Patients: Findings From The ARCANGELO Study.

Am J Cardiol

December 2024

Unità di Cardiologia IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address:

Outcome data on the use of cangrelor in older patients is limited. This post-hoc analysis of the ARCANGELO study aims to assess bleeding and ischemic outcomes with the transition from cangrelor to any oral P2Y inhibitors in age-stratified subgroups (≥75 years - older, <75 years - younger) of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Out of 995 patients, 215 (21.

View Article and Find Full Text PDF

Activation of PLCβ enzymes by G and G proteins is a common mechanism to trigger cytosolic Ca increase. We and others reported that G inhibitor FR900358 (FR) can inhibit both and G- and, surprisingly, G-mediated intracellular Ca mobilization. Thus, the G-G-PLCβ-Ca signaling axis depends entirely on the presence of active G, which reasonably explained FR-inhibited G-induced Ca release.

View Article and Find Full Text PDF

Objective: The optimal low-dose antiplatelet agents in patients with coronary heart disease (CHD) had not been determined. The objective of this study was to compare the impact of different low-dose antiplatelet agents on cardiovascular outcomes and bleeding risks in patients with CHD.

Methods: We searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, VIP, WanFang Data, and China Biology Medicine.

View Article and Find Full Text PDF

Switching Platelet P2Y Receptor Inhibiting Therapies.

Interv Cardiol Clin

October 2024

Division of Cardiology, University of Florida College of Medicine-Jacksonville, ACC Building 5th Floor, 655 West 8th Street, Jacksonville, FL 32209, USA.

Antiplatelet therapy involving aspirin and a P2Y receptor inhibitor is fundamental in managing patients with atherothrombotic disease. Switching between P2Y inhibitors is frequently observed in clinical settings for various reasons, such as safety, efficacy, patient adherence, or cost concerns. Although it occurs often, the optimal method for switching remains a concern owing to potential drug interactions, which can result in either inadequate platelet inhibition and subsequent thrombotic events or low platelet reactivity and increased bleeding risks due to therapy overlap.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!